National Bank of Greece Sa (NBG) 1.27 $NBG Contrarian

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
National Bank of Greece Sa (NBG) 1.27 $NBG

Contrarian Investors -- It's Time to Look Beyond National Bank of Greece
Alexander MacLennan, The Motley Fool - Motley Fool - Sun Mar 15, 9:05AM CDT
Due to its on-the-ground economic situation, as well as its debt troubles, Greece has attracted a lot of attention from contrarian investors looking for value and recovery. But many investors have focused on National Bank of Greece as if it's the...
GREK: 10.61 (-0.07), NBG: 1.27 (+0.04)

Market Updates on Diversified Banks Equities -- National Bank of Greece, ICICI Bank, Royal Bank of Canada, Bank of Montreal, and Bank of Nova Scotia
PR Newswire - Thu Mar 12, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BMO: 60.46 (+1.07), IBN: 11.00 (+0.05), RY: 59.85 (+0.69), NBG: 1.27 (+0.04), BNS: 50.08 (+0.94)

Greece to tap into bank rescue fund
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 1:03AM CDT

GREK: 10.61 (-0.07), NBG: 1.27 (+0.04)

National Bank Of Greece: Liquidity, Not Capital, Is The Main Concern
George Kesarios - at Seeking Alpha - Mon Mar 09, 1:34PM CDT

NBG: 1.27 (+0.04)

Short The National Bank Of Greece
Yehoshua Paul - at Seeking Alpha - Mon Mar 09, 10:49AM CDT

GREK: 10.61 (-0.07), NBG: 1.27 (+0.04)

Here's a Reason National Bank of Greece (NBG) Stock Is Declining Today
at The Street - Mon Mar 09, 8:37AM CDT
National Bank of Greece (NBG) stock is down as it is likely that no decision on Greece's bailout program will be made at today's Eurozone meeting in Brussels.
NBG: 1.27 (+0.04)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 8:12AM CDT

ACRX: 3.97 (-0.08), WLL: 38.25 (-1.75), RXII: 1.19 (+0.04), RMGN: 1.82 (+0.05), LBIO: 13.47 (+0.35), NBG: 1.27 (+0.04), CTIC: 1.99 (+0.02), RTI: 36.99 (-0.80), GLPI: 36.03 (+0.02), PNK: 34.72 (+0.33), CYTX: 1.33 (+0.13), AVEO: 1.30 (-0.10), MAC: 95.31 (+0.92)

National Bank of Greece (NBG) Stock Slumped Today as Greek Markets Declined
at The Street - Fri Mar 06, 2:51PM CST
Shares of National Bank of Greece (NBG) fell in afternoon trading today as Greek markets declined.
NBG: 1.27 (+0.04)

Why National Bank of Greece (ADR) Rocketed 43% Higher in February
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 06, 8:03AM CST
What: Shares of National Bank of Greece , Greece's largest bank by assets, skyrocketed 43% in February, based on data from S&P Capital IQ , following a bailout agreement reached between Greece and its creditors. So what: Talk about a wild...
NBG: 1.27 (+0.04)

Draghi: Greek debt not yet eligible for QE
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 8:10AM CST

GREK: 10.61 (-0.07), NBG: 1.27 (+0.04)

3 Financial Stocks Driving The Sector Higher
at The Street - Tue Mar 03, 11:03AM CST
TheStreet highlights 3 stocks pushing the financial sector higher today.
C: 53.61 (+0.07), LEAF: 51.43 (+1.59), NBG: 1.27 (+0.04)

National Bank of Greece (NBG) Stock Closed Lower Today as Greek Markets Declined
at The Street - Mon Mar 02, 3:09PM CST
Shares of National Bank of Greece (NBG) fell today as Greek markets declined.
NBG: 1.27 (+0.04)

ECB could reinstate Greek debt waiver
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 2:44AM CST

NBG: 1.27 (+0.04)

National Bank of Greece (NBG) Stock Falls Today Following Tuesday's Surge
at The Street - Wed Feb 25, 9:52AM CST
Shares of National Bank of Greece (NBG) were down in morning trading Wednesday, one day after the stock soared following the Eurozone's approval of Greece's reform plan.
NBG: 1.27 (+0.04)

National Bank of Greece (NBG) Stock Soaring Today as Bailout Extension Approved
at The Street - Tue Feb 24, 8:38AM CST
National Bank of Greece (NBG) stock is up today as the Eurozone finance ministers approved Greece's reform plan.
BLK: 374.36 (+6.62), NBG: 1.27 (+0.04)

National Bank of Greece (NBG) Stock Falls Today Despite Greek Bailout Extension
at The Street - Mon Feb 23, 8:57AM CST
Shares of National Bank of Greece (NBG) were down Monday despite the agreement reached by the Eurozone and Greece on Friday to extend the nation's bailout by four months.
NBG: 1.27 (+0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 9

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

A Comprehensive Look at Apple's Competitive Position in Tech

Updated Category News Views 313

Understanding Apple's Competitive Landscape In today's dynamic business environment, a deep-dive analysis of top companies is essential for investors and industry insiders. This examination will focus on Apple (AAPL), alongside its chief rivals in the Technology Hardware, Storage & Peripherals sector. By analyzing crucial financial indicators, market positioning, and...

Continue Reading
Cegedim Shares Insights on Latest Liquidity Contract Performance

Updated Category News Views 135

Overview of Cegedim's Liquidity Contract Statement This article covers the latest updates on Cegedim’s liquidity contract performance, highlighting significant figures and trends that reflect the company's financial health. Cegedim has established a robust liquidity contract with Rothschild Martin Maurel, aimed at promoting transparency and liquidity in its shares. Key...

Continue Reading
Silexion Therapeutics Advances SIL204 for Pancreatic Cancer

Updated Category News Views 136

Silexion Therapeutics Moves Forward with SIL204 Silexion Therapeutics Corp. (NASDAQ: SLXN) is celebrating a significant milestone with the completion of crucial toxicology studies for its innovative RNA silencing therapy, SIL204. This groundbreaking therapy, designed to target mutated KRAS oncogenes, has shown no signs of systemic organ toxicity, reinforcing the...

Continue Reading
Emerson Partners with LifeSight for Enhanced Pension Solutions

Updated Category News Views 178

Emerson Partners with LifeSight for Pension Solutions LifeSight, WTW’s UK defined contribution (DC) master trust, has stepped into a significant role by becoming the full master trust provider for Emerson, the advanced electronics powerhouse. This partnership aims to cover all active, deferred, and drawdown members effectively, ensuring they are well-accommodated in...

Continue Reading
Howard Marks Joins Alliance for Decision Education Board

Updated Category News Views 227

Exciting News from the Alliance for Decision Education The Alliance for Decision Education is thrilled to announce an important addition to its Board of Directors. Howard Marks, a leader in investment management and a well-respected voice in decision-making, has agreed to join the board. As the co-chairman and co-founder of Oaktree Capital Management, Marks brings with...

Continue Reading